Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

No BS RX vs Wellorithm

By GLP-1 ScorecardUpdated

No BS RXFactor scores not reassessed.
Site position #23

Higher score

WellorithmFactor scores not reassessed.
Site position #502

Lower score

Score comparison

No BS RX has the higher recorded score — 82.8/100 to 48.5/100.

No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.

Before you choose

Before comparing the headline prices, the No BS RX review and the Wellorithm review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, No BS RX vs Wholesome Clinic and Ro vs Wellorithm compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNo BS RX +62
92
30
Dose & formulationWellorithm +2
90
92
Clinical oversightNo BS RX +44
72
28
Labs & monitoringNo BS RX +28
68
40
FulfillmentNo BS RX +32
94
62
Contract termsNo BS RX +29
74
45
No BS RX · top barWellorithm · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNo BS RXWellorithm
WeighScore82.8/10048.5/100
GradeB−C
Site position#23#502
Semaglutide$149/mo advertised for standard compounded injection; low-dose priced separately$179 first payment; $299 ongoing for compounded injection. Pricing says monthly; terms say every 28 days. Initial consultation and shipping included; usable supply unconfirmed.
Tirzepatide$225/mo advertised for standard compounded injection; low-dose priced separately$279 first payment; $399 ongoing for compounded injection. Pricing says monthly; terms say every 28 days. Initial consultation and shipping included; usable supply unconfirmed.
CoverageConfirm program availability for your stateAdvertises all 50 states plus D.C.; confirm the specific treatment, prescribing clinician and dispensing pharmacy for your location.
Brand-name accessYesYes
Oral / sublingualYesYes
No BS RX

Site position #23 · B−

Factor scores not reassessed.

Strengths

  • Displays monthly and prepaid amounts by program
  • Advertises consultation, medication, shipping and messaging in the compounded plans
  • Lists branded Ozempic and Zepbound separately

What to consider

  • The $115 headline applies to low-dose programs
  • Plans renew automatically at the then-current rate
  • Cancellation generally stops future billing without refunding the current period
Wellorithm

Site position #502 · C

Factor scores not reassessed.

Strengths

  • Publishes first and ongoing compounded injection charges separately
  • Advertises the same medication price across its listed weekly dose ranges
  • Initial consultation and shipping included in injection plan cards
  • Lists four branded options and a generic oral dissolving-tablet option; exact quote and prescription still needed

What to consider

  • Pricing says monthly renewal, while terms say billing every 28 days
  • Oral ingredient, strength, supply and price not specified in the public injection table
  • Branded pages carry inconsistent three-month/500mg footnotes; insurance service and cash-only terms need reconciliation
  • Treating Professional Entities and dispensing pharmacy unnamed in the reviewed policies
  • Consultation fee retention on clinical rejection is not quantified; processed-payment refunds are restricted

Featured provider

Wellorithm

Factor scores not reassessed.

Wellorithm scores 48.5/100 (C). Public first and ongoing injection prices, with unresolved monthly-versus-28-day billing and separately qualified oral and branded offers.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard